STOCK TITAN

Neogen® Launches New Molecular Method for Detection of Two Salmonella Serotypes

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Neogen® introduced the Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST) to add to their pathogen testing platform, helping enhance food safety in the poultry industry. The new assay offers improved accuracy, reduced time to results, and a streamlined workflow. It detects specific Salmonella serotypes, aiding in reducing foodborne illness. The product has been approved by the AOAC® Research Institute, and it is part of the award-winning Neogen Molecular Detection System platform.

Neogen® ha introdotto il test Neogen Molecular Detection Assay 2 - Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST), ampliando la propria piattaforma di test per patogeni e migliorando la sicurezza alimentare nell'industria avicola. Questo nuovo test offre maggiore accuratezza, riduce i tempi di ottenimento dei risultati e semplifica il flusso di lavoro. Rileva specifici sierotipi di Salmonella, contribuendo alla riduzione delle malattie trasmesse da alimenti. Il prodotto è stato approvato dall'Istituto di Ricerca AOAC® ed è parte della premiata piattaforma Neogen Molecular Detection System.
Neogen® ha presentado el Neogen Molecular Detection Assay 2 - Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST) para ampliar su plataforma de pruebas de patógenos, ayudando a mejorar la seguridad alimentaria en la industria avícola. Este nuevo ensayo ofrece mayor precisión, reduce el tiempo para obtener resultados y simplifica el flujo de trabajo. Detecta serotipos específicos de Salmonella, ayudando a reducir las enfermedades transmitidas por alimentos. El producto ha sido aprobado por el Instituto de Investigación AOAC® y forma parte de la galardonada plataforma Neogen Molecular Detection System.
Neogen®은 가금류 산업에서 식품 안전을 향상시키기 위해 병원체 검사 플랫폼에 Neogen Molecular Detection Assay 2 - Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST)를 추가했습니다. 이 새로운 분석 도구는 정확성을 향상시키고 결과를 더 빠르게 제공하며 통합된 작업 흐름을 제공합니다. 특정 살모넬라 혈청형을 검출하여 식중독 감소에 도움을 줍니다. 이 제품은 AOAC® 연구소에서 승인을 받았으며, 수상 경력이 있는 Neogen Molecular Detection System 플랫폼의 일부입니다.
Neogen® a introduit l'analyse Neogen Molecular Detection Assay 2 - Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST) pour renforcer sa plateforme de tests de pathogènes, améliorant ainsi la sécurité alimentaire dans l'industrie de la volaille. Ce nouveau test offre une meilleure précision, réduit le temps pour obtenir des résultats et simplifie le flux de travail. Il détecte les sérotypes spécifiques de Salmonella, contribuant à réduire les maladies d'origine alimentaire. Le produit a été approuvé par l'Institut de Recherche AOAC® et fait partie de la plateforme récompensée Neogen Molecular Detection System.
Neogen® hat den Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST) eingeführt, um seine Plattform für Pathogentests zu erweitern und die Lebensmittelsicherheit in der Geflügelindustrie zu verbessern. Der neue Test bietet verbesserte Genauigkeit, verkürzte Ergebniszeiten und einen vereinfachten Arbeitsablauf. Er erkennt spezifische Salmonellen-Serotypen, was zur Reduzierung von lebensmittelbedingten Krankheiten beiträgt. Das Produkt wurde vom AOAC® Forschungsinstitut genehmigt und ist Teil des preisgekrönten Neogen Molecular Detection System.
Positive
  • Neogen® launched the Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST) to enhance food safety in the poultry industry, offering improved accuracy, reduced time to results, and a streamlined workflow.
  • The new assay aids in reducing foodborne illness by detecting specific Salmonella serotypes, Salmonella Enteritidis and Salmonella Typhimurium, which are pathogenic to humans.
  • The Neogen MDA2SEST received approval from the AOAC® Research Institute Performance Tested MethodsSM (PTM) Program, ensuring its method performance quality and reliability.
  • The Neogen Molecular Detection System platform, where the MDA2SEST is integrated, is used worldwide and offers fast, accurate, and affordable pathogen testing solutions for various entities, including food processors and universities.
Negative
  • None.

LANSING, Mich., April 30, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), a worldwide leader in innovative solutions that help the food and beverage industries ensure safety and quality in their products, announced today the launch of the new Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST).

The product joins several other next-generation assays, including Salmonella, E. coli O157 (including H7), Listeria and Listeria monocytogenes, Campylobacter, STEC gene screen (stx and eae), and Cronobacter, as part of the Neogen Molecular Detection System pathogen testing platform.

"We are pleased to bring this advanced technology to our customers, helping them to enhance their food safety program and address a challenging need in the poultry industry," said John Adent, Neogen's President and CEO. "This isothermal molecular assay overcomes certain limitations of existing solutions, such as traditional serology and PCR-based methods, with improved accuracy, reduced time to results, and a streamlined workflow that provides increased productivity and unparalleled ease of use."

The Neogen MDA2SEST kit is used with the Neogen Molecular Detection System for rapid and specific detection of two Salmonella serotypes, Salmonella enterica subsp. enterica serotype Enteritidis (SE) and Salmonella enterica subsp. enterica serotype Typhimurium (including monophasic variant 1,4,[5],12:i:-) (ST), in enriched poultry samples. Salmonella Enteritidis and Salmonella Typhimurium are two serotypes that are pathogenic to humans and have been implicated in Salmonella outbreaks. By enabling the detection of specific serotypes such as S. Enteritidis and S. Typhimurium, the MDA2SEST assay is an important tool that can help reduce foodborne illness.

The Neogen MDA2SEST was granted approval by the AOAC® Research Institute Performance Tested MethodsSM (PTM) Program and assigned PTM Certification No. 122302. The PTM Program provides independent third-party review and certification for proprietary test method performance.

The award-winning Neogen Molecular Detection System platform is used by food processors, universities, governments, and contract testing laboratories in more than 40 countries. It is powered by a combination of advanced technologies—isothermal DNA amplification and bioluminescence detection—to provide a pathogen testing solution that is fast, accurate, easy to use, and affordable. The new assay for Salmonella Enteritidis and Salmonella Typhimurium joins, and can be run concurrently with, molecular tests already offered by Neogen for Salmonella, E. coli O157 (including H7), Listeria and Listeria monocytogenes, Campylobacter, STEC gene screen (stx and eae), and Cronobacter.

Individuals interested in this new technology may contact their local Neogen Food Safety representative or visit https://www.neogen.com/molecular-detection-system to learn more.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

Contact

Jean-Yves Mazzitelli | Global Product Owner, Food Safety
JMazzitelli@Neogen.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-launches-new-molecular-method-for-detection-of-two-salmonella-serotypes-302131018.html

SOURCE Neogen Corporation

Neogen Corp

NASDAQ:NEOG

NEOG Rankings

NEOG Latest News

NEOG Stock Data

2.63B
216.12M
0.27%
119.34%
10.67%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
LANSING